European Counsel

Munich +

Korel Kaplan advises financial sponsors, industrial corporate clients, and emerging technology companies on complex M&A transactions and strategic board and corporate matters. He has advised clients on cross-border deals and critical governance matters across the tech, automotive, energy, financial, and health care industries.

Korel regularly structures, drives, negotiates, and closes critical M&A transactions involving acquisitions or divestments of companies, competitive auctions, joint ventures, carve-outs, co-investments, and financing rounds. He has particular experience with leveraged buyouts, shareholder and investment agreements, buy-and-build strategies, large corporate carve-out deals, transactions triggering complex merger control or investment protection scrutiny, management participation programs, and transactional insurance products including warranty and indemnity (W&I) insurance.

Korel provides boardroom advice to management and supervisory boards on directors liability, corporate governance and best practices, general compliance matters, reorganizations, and negotiations or disputes requiring in-depth transactional or corporate law experience.

Prior to joining Jones Day, Korel practiced at an international firm where he advised financial sponsors such as Apax, BC Partners, Catella Group, Intek Group, Ontario Teachers' Pension Plan, SINO-CEEF, and Triton as well as corporate clients including Audi, BayWa, Continental, innogy, KME SE, lastminute.com group, Schneider Electric, and Ströer.


  • EMERAM Capital Partners sells portfolio company MEONA to Trill ImpactJones Day represented EMERAM Capital Partners GmbH, one of the leading investment companies for medium-sized companies in the German-speaking region, in the sale of its portfolio company MEONA, an innovation leader for clinical software, to the private equity firm, Trill Impact.
  • Astellas returns rights to Eligard® in Europe, Middle East, CIS, and Asia to TolmarJones Day represented Astellas Pharma Europe Ltd. in connection with a series of transactions, including the sale of related assets, in which Astellas returned its in-licensing rights to Eligard® (leuprorelin acetate for injectable suspension), a treatment for advanced prostate cancer, sold by Astellas in Europe, the Middle East, the Commonwealth of Independent States (CIS) and Asia, to Tolmar International Limited.
  • Astellas transfers DIFICLIR in Europe, Middle East, Africa, and selected CIS to Swiss Tillotts Pharma AG for €109 millionJones Day advised Astellas Pharma Europe Ltd. on the sale of distribution rights to the product "DIFICLIR" in Europe, Middle East, Africa, and selected Commonwealth of Independent States (CIS) countries to Swiss Tillotts Pharma AG for €109 million.
  • Materion acquires Optics Balzers, AG for $160 millionJones Day advised Materion Corporation, a global supplier of highly engineered advanced enabling materials, in its $160 million acquisition of Optics Balzers, AG, an industry leader in thin film optical coatings.
  • ebase GmbH to acquire securities business of Augsburger AktienbankJones Day is advising European Bank of Financial Services GmbH (ebase) in the acquisition of the securities business of Augsburger Aktienbank AG.
  • yabeo Advisors participates in €60 million Series C financing round of solarisBank AGJones Day advised yabeo Advisors GmbH in its minority stake investment in solarisBank AG, Europe's leading Banking-as-a-Service platform.
  • Edge Case Research acquires TerraLoupe TechnologyJones Day advised Edge Case Research, Inc. in its acquisition of assets of TerraLoupe GmbH.